Back to Authors

Roberts, Andrew W.

https://orcid.org/0000-0002-7341-5720

A5033407869 | I1320473756

Mayo Clinic

The Royal Melbourne Hospital

Citations 13

Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8011-8011

10.1200/jco.2016.34.15_suppl.8011

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Blood | August 29, 2017 | Volume: 130 | Issue: 22 | Pages: 2392-2400

10.1182/blood-2017-06-788323 | PMID 28847998

Key Points In relapsed/refractory MM, venetoclax plus bortezomib and dexamethasone appears to be safe and efficacious. This is a novel therapeutic approach for MM.
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Blood | March 11, 2015 | Volume: 125 | Issue: 17 | Pages: 2649-2655

10.1182/blood-2013-02-484832 | PMID 25762180

Key Points Pacritinib reduced myelofibrosis-related splenomegaly and patient symptoms without causing clinically significant myelosuppression. Pacritinib had activity and was well tolerated in patients with preexisting anemia and thrombocytopenia.